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Background: Inﬂuenza immunization proved to be effec-
tive in decreasing pneumonia hospitalizations in the elderly
and in patients with high-risk conditions. The purpose of this
study was to assess the effectiveness of inﬂuenza vaccine in
persons + 65 years with chronic pulmonary and cardiovascu-
lar diseases during four immunization campaign seasons in
Argentina.
Methods: Inﬂuenza vaccines containing the strains specif-
ically recommended by the WHO were administered free of
charge in immunization campaigns from 1994 to 1999. Dur-
ing campaigns, demographic data and disease status of each
subject who was immunized was obtained through interview
before vaccine was administered. Subjects with chronic
pulmonary (CPD) and cardiovascular disease (CVD) were ret-
rospectively evaluated for hospitalization due to pneumonia
during the previous inﬂuenza season (June-October;1995-
1998) and vaccination status.
Results: A total of 176.778 people with CVD and 82.385
with CPD were evaluated. Annual inﬂuenza vaccine effec-
tiveness for reduction of pneumonia hospitalization was:
1995%
(95%CI)
1996%
(95%CI)
1997%
(95%CI)
1998%
(95%CI)
CVD 43 (33-52) 36 (28-46) 29 (18-38) 37 (26-46)
CPD 41 (32-48) 35 (27-41) 27 (19-35) 27 (18-35)
Conclusion: Inﬂuenza vaccination is associated with a sig-
niﬁcant reduction in hospitalization rates due to community
acquired pneumonia in the elderly population in Argentina,
particularly in those with high-risk conditions. Widespread
use of inﬂuenza vaccine should be promoted.
doi:10.1016/j.ijid.2010.02.624
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Background: Rabies is a fatal but preventable. In the past
decade attempts have been made to develop an effective
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NA vaccine against rabies. However, the effectiveness of
lasmid DNA vaccines is limited due to ineffective intracel-
ular gene delivery. Recently, a group of compounds called
endrimers have been shown to mediate effective gene
elivery. In this study we have developed a novel, polether-
mine (PETIM) dendrimer-based nano-formulated plasmid
NA rabies vaccine and evaluated its immunogenicity.
Methods: The full length glycoprotein gene of rabies
irus was cloned into the expression vector pIRES and its
xpression veriﬁed. Fourth generation amine-terminated
olyetherimine (PETIM) dendrimer was synthesized and
haracterized. PETIM-pDNA complexes were prepared at
arying ratios and their size, shape, transfection efﬁ-
iency and cytotoxicity were studied. In vitro transfection
xperiments were conducted to identify the formulation
ossessing maximal transfection ability. The ability of the
endrimer to protect the encapsulated DNA was studied by
eoxyribonuclease protection assay. The in vivo efﬁcacy of
he dendrimer-DNA complexes was evaluated by studying
he virus neutralizing antibody responses in Swiss albino
ice immunized with these formulations, in comparison
ith those produced by unmodiﬁed plasmid DNA.
Results: The PETIM dendrimer was found to be non-
oxic to cultured mammalian cells upto 1mg/mL. It was
lso observed to protect the complexed DNA from nuclease
egradation. The PETIM-DNA complexes were also observed
o produce satisfactory expression of the encoded gene in
ransfected cells. The animals immunized intramuscularly
ith the dendrimeric formulations of plasmid DNA produced
dequate titres of protective, rabies-virus neutralizing anti-
odies by 2 weeks post-vaccination, after a single dose.
he mean titre of neutralizing antibody was higher (1:512)
n mice immunized with the dendrimeric formulations than
n the group immunized with the unmodiﬁed plasmid DNA
1:16) (p < 0.05).
Conclusion: The fourth generation polyetherimine den-
rimer is a promising nano-carrier for plasmid DNA rabies
accines. Its utility in immunization of larger animals and
umans needs to be evaluated further.
oi:10.1016/j.ijid.2010.02.625
3.023
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Background: Among the top ten causes of poor health in
he district are complications due to vaccine preventable
iseases notably diphtheria, pertussis and tetanus (DPT). In
